Absci Corporation (ABSI) Secures $64M Financing to Drive AI Drug Discovery Through 2028

Absci Corporation (ABSI) raised $64m in equity financing to drive AI drug discovery through 2028. The funding will support the advancement of key pipeline programs, including ABS-101 and ABS-201, while accelerating partnered projects and strengthening the corporation's AI infrastructure. ABSI is pioneering the integration of deep learning with high-throughput lab automation to design and optimize biologics at scale. Its Integrated Drug Creation (IDC) platform combines proprietary algorithms with protein engineering, enabling rapid development of antibody and enzyme candidates for both pharma partners and its own pipeline.